Doxapram Treatment and Diaphragmatic Activity in Preterm Infants

Cornelia G. de Waal, Gerard J. Hutten, Juliette V. Kraaijenga, Frans H. de Jongh, Anton H. van Kaam

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Background: Doxapram is a treatment option for severe apnea of prematurity (AOP). However, the effect of doxapram on the diaphragm, the main respiratory muscle, is not known. Objectives: To investigate the effect of doxapram on diaphragmatic activity measured with transcutaneous electromyography of the diaphragm (dEMG). Methods: A pilot study was conducted in a tertiary neonatal intensive care unit. Diaphragmatic activity was measured from 30 min before up to 3 h after the start of doxapram treatment. dEMG parameters were compared to baseline (5 min before doxapram treatment) and at 15, 60, 120 and 180 min after the start of doxapram infusion. Results: Eleven preterm infants were included with a mean gestational age of 25.5 ± 1.2 weeks and birth weight of 831 ± 129 g. The amplitudedEMG, peakdEMG and tonicdEMG values did not change in the 3 h after the start of doxapram infusion compared to baseline. Clinically, the number of apnea episodes in the 24 h after doxapram treatment decreased significantly. Conclusion: Doxapram infusion does not alter diaphragmatic activity measured with transcutaneous dEMG in preterm infants with AOP, indicating that its working mechanism is primarily on respiratory drive and not on respiratory muscle activity.
Original languageEnglish
Pages (from-to)85-88
Number of pages4
JournalNeonatology
Volume115
Issue number1
Early online date2018
DOIs
Publication statusPublished - 1 Jan 2019

Cite this

de Waal, C. G., Hutten, G. J., Kraaijenga, J. V., de Jongh, F. H., & van Kaam, A. H. (2019). Doxapram Treatment and Diaphragmatic Activity in Preterm Infants. Neonatology, 115(1), 85-88. https://doi.org/10.1159/000493359
de Waal, Cornelia G. ; Hutten, Gerard J. ; Kraaijenga, Juliette V. ; de Jongh, Frans H. ; van Kaam, Anton H. / Doxapram Treatment and Diaphragmatic Activity in Preterm Infants. In: Neonatology. 2019 ; Vol. 115, No. 1. pp. 85-88.
@article{812b5ed247aa476f9cd2326a4fc68ede,
title = "Doxapram Treatment and Diaphragmatic Activity in Preterm Infants",
abstract = "Background: Doxapram is a treatment option for severe apnea of prematurity (AOP). However, the effect of doxapram on the diaphragm, the main respiratory muscle, is not known. Objectives: To investigate the effect of doxapram on diaphragmatic activity measured with transcutaneous electromyography of the diaphragm (dEMG). Methods: A pilot study was conducted in a tertiary neonatal intensive care unit. Diaphragmatic activity was measured from 30 min before up to 3 h after the start of doxapram treatment. dEMG parameters were compared to baseline (5 min before doxapram treatment) and at 15, 60, 120 and 180 min after the start of doxapram infusion. Results: Eleven preterm infants were included with a mean gestational age of 25.5 ± 1.2 weeks and birth weight of 831 ± 129 g. The amplitudedEMG, peakdEMG and tonicdEMG values did not change in the 3 h after the start of doxapram infusion compared to baseline. Clinically, the number of apnea episodes in the 24 h after doxapram treatment decreased significantly. Conclusion: Doxapram infusion does not alter diaphragmatic activity measured with transcutaneous dEMG in preterm infants with AOP, indicating that its working mechanism is primarily on respiratory drive and not on respiratory muscle activity.",
keywords = "Diaphragm, Doxapram, Transcutaneous electromyography",
author = "{de Waal}, {Cornelia G.} and Hutten, {Gerard J.} and Kraaijenga, {Juliette V.} and {de Jongh}, {Frans H.} and {van Kaam}, {Anton H.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1159/000493359",
language = "English",
volume = "115",
pages = "85--88",
journal = "Neonatology",
issn = "1661-7800",
publisher = "S. Karger AG",
number = "1",

}

de Waal, CG, Hutten, GJ, Kraaijenga, JV, de Jongh, FH & van Kaam, AH 2019, 'Doxapram Treatment and Diaphragmatic Activity in Preterm Infants' Neonatology, vol. 115, no. 1, pp. 85-88. https://doi.org/10.1159/000493359

Doxapram Treatment and Diaphragmatic Activity in Preterm Infants. / de Waal, Cornelia G.; Hutten, Gerard J.; Kraaijenga, Juliette V.; de Jongh, Frans H.; van Kaam, Anton H.

In: Neonatology, Vol. 115, No. 1, 01.01.2019, p. 85-88.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Doxapram Treatment and Diaphragmatic Activity in Preterm Infants

AU - de Waal, Cornelia G.

AU - Hutten, Gerard J.

AU - Kraaijenga, Juliette V.

AU - de Jongh, Frans H.

AU - van Kaam, Anton H.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background: Doxapram is a treatment option for severe apnea of prematurity (AOP). However, the effect of doxapram on the diaphragm, the main respiratory muscle, is not known. Objectives: To investigate the effect of doxapram on diaphragmatic activity measured with transcutaneous electromyography of the diaphragm (dEMG). Methods: A pilot study was conducted in a tertiary neonatal intensive care unit. Diaphragmatic activity was measured from 30 min before up to 3 h after the start of doxapram treatment. dEMG parameters were compared to baseline (5 min before doxapram treatment) and at 15, 60, 120 and 180 min after the start of doxapram infusion. Results: Eleven preterm infants were included with a mean gestational age of 25.5 ± 1.2 weeks and birth weight of 831 ± 129 g. The amplitudedEMG, peakdEMG and tonicdEMG values did not change in the 3 h after the start of doxapram infusion compared to baseline. Clinically, the number of apnea episodes in the 24 h after doxapram treatment decreased significantly. Conclusion: Doxapram infusion does not alter diaphragmatic activity measured with transcutaneous dEMG in preterm infants with AOP, indicating that its working mechanism is primarily on respiratory drive and not on respiratory muscle activity.

AB - Background: Doxapram is a treatment option for severe apnea of prematurity (AOP). However, the effect of doxapram on the diaphragm, the main respiratory muscle, is not known. Objectives: To investigate the effect of doxapram on diaphragmatic activity measured with transcutaneous electromyography of the diaphragm (dEMG). Methods: A pilot study was conducted in a tertiary neonatal intensive care unit. Diaphragmatic activity was measured from 30 min before up to 3 h after the start of doxapram treatment. dEMG parameters were compared to baseline (5 min before doxapram treatment) and at 15, 60, 120 and 180 min after the start of doxapram infusion. Results: Eleven preterm infants were included with a mean gestational age of 25.5 ± 1.2 weeks and birth weight of 831 ± 129 g. The amplitudedEMG, peakdEMG and tonicdEMG values did not change in the 3 h after the start of doxapram infusion compared to baseline. Clinically, the number of apnea episodes in the 24 h after doxapram treatment decreased significantly. Conclusion: Doxapram infusion does not alter diaphragmatic activity measured with transcutaneous dEMG in preterm infants with AOP, indicating that its working mechanism is primarily on respiratory drive and not on respiratory muscle activity.

KW - Diaphragm

KW - Doxapram

KW - Transcutaneous electromyography

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85055816180&origin=inward

UR - https://www.ncbi.nlm.nih.gov/pubmed/30352445

U2 - 10.1159/000493359

DO - 10.1159/000493359

M3 - Article

VL - 115

SP - 85

EP - 88

JO - Neonatology

JF - Neonatology

SN - 1661-7800

IS - 1

ER -

de Waal CG, Hutten GJ, Kraaijenga JV, de Jongh FH, van Kaam AH. Doxapram Treatment and Diaphragmatic Activity in Preterm Infants. Neonatology. 2019 Jan 1;115(1):85-88. https://doi.org/10.1159/000493359